Musculoskeletal Disorders
From the Journals
JIA Treatment Has Increasingly Involved New DMARDs Since 2001
An analysis of a large population of commercially insured children with juvenile idiopathic arthritis in the US showed an increasing popularity of...
From the Journals
US Experience With Infliximab Biosimilars Suggests Need for More Development Incentives
Use of infliximab biosimilars in the United States rose slowly until three were on the market; it continued to remain lower for Medicare than for...
News from the FDA/CDC
Pyzchiva Receives FDA Approval as Third Ustekinumab Biosimilar
The biosimilar is approved for all indications of the reference medication, Stelara, and will launch in February 2025.
Conference Coverage
First-line Canakinumab Without Steroids Shows Effectiveness for Systemic Juvenile Idiopathic Arthritis
For JIA, a disease with limited options, a three-injection course of canakinumab was associated with durable control of disease in the absence of...
News from the FDA/CDC
FDA Approves Polyarticular JIA Indication for Sarilumab
The approval applies to patients weighing at least 63 kg, the announcement said.
News from the FDA/CDC
FDA Grants New Pediatric Arthritis Indications for Upadacitinib
The JAK inhibitor’s safety profile for patients as young as 2 years was similar to the known safety profile in adults.
From the Journals
Durable Tocilizumab Responses Seen in Trial Extensions of Polyarticular and Systemic JIA Subtypes
Patients with juvenile idiopathic arthritis achieved long-term disease control with subcutaneous tocilizumab treatment, without any new safety...
Conference Coverage
Clinical Characteristics of Chronic Nonbacterial Osteomyelitis Can Predict Therapy Needs Over Time
Patients with unifocal disease at diagnosis may require shorter nonsteroidal anti-inflammatory drug monotherapy courses than those with multifocal...
Latest News
Visionary Surgery Saved Pitcher’s Arm. Now Even Children Get It
One study concluded that 67.4% of ulnar collateral ligament reconstruction surgeries were performed on athletes between 16 and 20 years of age.
Conference Coverage
Early Biologic Initiation Linked to Rapid Improvement of JIA, Sustained Remission
The findings have implications for insurance rules that require patients to take a conventional DMARD for a minimum period before initiating...
News from the FDA/CDC
Second FDA-Approved Tocilizumab Biosimilar Has Intravenous, Subcutaneous Formulations
It’s unclear when the new tocilizumab products will be commercially available.